Researchers of the review are underscoring the potential for economic policies to improve the management of hypertension for the millions of people throughout the United States with the condition who are at risk for cardiovascular disease.
Expanding insurance coverage and offering financial incentives may improve the quality of hypertension management, and subsequently improve outcomes, say findings of a systematic review.
Compiling randomized controlled trials, difference-in-differences, and interrupted time series studies between 2000 and 2023, researchers of the review are underscoring the potential for economic policies to improve the management of hypertension for the millions of people throughout the United States with the condition who are at risk for cardiovascular disease. They published their findings in JAMA Health Forum.
“To address the pressing issue of uncontrolled hypertension and its associated risks, it is essential to consider broad-scale actions. Economic policies such as minimum wages, unemployment benefits, and Medicaid expansion might be potential interventions to improve hypertension control, by reducing cost-related barriers to health care among people with lower incomes,” wrote the researchers. “Economic policies that address health-related social needs, such as the Supplemental Nutrition Assistance Program (SNAP), might also have an effect on hypertension-related outcomes. Other economic policies, such as cost control policies or reimbursement models, may have unintended consequences and potentially reduce hypertension control.”
To date, explained the researchers, insights into the associations between these policies and patient outcomes has remained limited. For their literature review, the researchers used various databases, including PubMed/MEDLINE, EconLit, and Scopus. The group noted that 7 studies used self-reported assessment of medication use and blood pressure.
All but 1 of the 16 coverage expansion-related studies indicated that Medicaid expansion and other coverage expansions were associated with statistically significant improvements in treatment for hypertension and blood pressure control. Eleven of these studies assessed the impact of Medicaid expansion, 10 of which found positive associations with outcomes. Another found a significant reduction in systolic blood pressure but not diastolic blood pressure.
The outlier study—the landmark Oregon Health Insurance Experiment—did not find a significant impact of coverage expansion on blood pressure control. The researchers noted that differences in findings between this study and the rest may be explained by differences in study population (nationwide vs statewide) as well as how long after expansion implementation the study was done.
The other 4 of these studies assessed the impact of Medicare Part D expansion, and all showed statistically significant improvements in blood pressure control, as well as increases in the amount of prescriptions written and filled for medications for antihypertensive medications, and adherence to these prescriptions.
Financial incentives, assessed in 7 studies, were shown to improve treatment adherence and blood pressure control. The researchers noted that while programs, such as pay-per-performance programs, are typically initiated at a local level, the findings signal that targeted policies and novel payment and delivery approaches could help achieve hypertension management at a national level.
There were 8 studies offering insight into cost-sharing policies, including prior authorization for Medicaid, monthly prescription limits, and higher copays for antihypertensive drugs. Examples of these policies include a Medicaid program in Louisiana that limits patients to receiving 8 prescriptions per month. Policies like copayments on treatment for hypertension, explained the researchers, may discourage use, increase costs for patients, and reduce adherence.
“In response to concerns about the policy’s potential adverse effects on hypertension control, the Centers for Medicare and Medicaid Services has introduced a new rule proposal,” wrote the researchers. “The primary goal of the proposal is to enhance patient and clinician access to health information while streamlining the prior authorization process and promoting efficiency and transparency. These changes may improve hypertension treatment.”
Across the 8 studies, the researchers observed mixed results. Half the studies found that such policies had a negative association on treatment use, while 2 showed a positive association and 2 showed no association.
Reference
Zhang D, Lee JS, Pollack LM, et al. Association of economic policies with hypertension management and control: A systematic review. JAMA Health Forum. 2024;5(2):e235231.doi:10.1001/jamahealthforum.2023.5231
Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation
May 18th 2024Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Health Equity and Access Weekly Roundup: May 18, 2024
May 18th 2024The US Senate hosted a panel addressing physician and health care shortages and efforts to increase minority representation in the medical field. An expert discussed initiatives to prevent senior homelessness. Advocates called for the repeal of the Comstock Act. Regulatory reforms are called for to improve rural cancer patients' access to pharmacies. Research reveals the impact of denials on patient access to immunology treatments.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More